A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology applications Dec. 15, 2025 -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced

Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HIT It is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds. Orphan Drug and Fast Track designations from the FDA Dec. 11, 2025 -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today

Dec. 11, 2025 -- Autobahn Labs (“Autobahn”), a venture studio focused on transforming high-potential academic science into investable drug discovery and development programs, announced today a strategic partnership with global life sciences company Astellas Pharma Inc. (“Astellas”). The collaboration seeks to advance academic research and discoveries into novel therapeutics, providing Astellas’ Innovation Lab and Oncology Research units with integrated visibility into promising platforms, techn

U.S. Losartan market totals $245M annually with 71M prescriptions Dec. 10, 2025 -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, and Blink Rx LLC (“BlinkRx”), one of the most advanced patient access platforms for branded medicat

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving AbbVie’s Long-Term Commitment December 8th, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced an amendment to its partnership agreement with AbbVie regarding ABBV-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently i

Dr. Reddy’s receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales Dec. 08, 2025 -- Immutep Limited (ASX: IMM; NASDAQ: IMM

Dec. 05, 2025 -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the “Scheme”) pursuant to which XRA 5 Corp. (“Sub”), a wholly-owned subsidiary of XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA Royalty”) will acquire the entire issued and to be issued share capital of Mural, became effective today, 5 December 2025 (the “Effective Date”). Distribution of cheques and cred

Dec. 04, 2025 -- SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea, a leading global contract research organization (CRO), today announced a strategic collaboration agreement between the two companies. This partnership aims to streamline development, accelerate timelines and bring advanced therapies to patients faster. This collaboration represents a forward-looking model for how CDMOs and CROs can collaborate to deliver synchronized solutio

Dec. 05, 2025 -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology plc (“Mural”) (Nasdaq: MURA) (the “Acquisition”) pursuant to an Irish High Court sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the “Scheme”). Mural shareholders received $2.035 in cash per

Dec. 02, 2025 -- Citizen Health today announced a new strategic partnership with UCB, a global biopharmaceutical leader in neurological and autoimmune research and development. The multi-year collaboration launches with a focus on epilepsy and five rare disease indications. By combining Citizen Health’s advanced AI-driven patient insights and advocacy networks with UCB’s expertise in drug development, the partnership aims to help deliver faster, more patient-centered solutions. Citizen Health